Recent advancements in pharmacological approaches to modulate GPX4 activity and expression, such as covalent inhibitors (e.g., LOC1886), proteolysis targeting chimera degraders (e.g., dGPX4), and cell-type-specific degraders (e.g., N6F11), offer promising strategies for inducing ferroptosis as a therapeutic intervention in cancer treatment[29]. The gene discussed is GPX4; the disease is cancer.